|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||1.6900 - 1.6900|
|52 Week Range||0.7400 - 1.7100|
|Beta (3Y Monthly)||0.25|
|PE Ratio (TTM)||84.50|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
ACADIA Pharmaceuticals Inc. (ACAD), Neuren Pharmaceuticals Limited (NEU.AX), and Rettsyndrome.org (RSO) announced today that the positive results from a Phase 2 study conducted by Neuren, which evaluated the safety and efficacy of trofinetide in females with Rett syndrome (RTT), have been published in Neurology®, the medical journal of the American Academy of Neurology.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...